Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition.
- Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions?
- A QMS That Anticipates Cell And Gene Therapy Quality Challenges
- Using Digital Platforms To Find Your CDMO
- July 2026 — CDMO Opportunities And Threats Report
- ADC CDMO Selection For Small Biotech
- Implementing AI Solutions In GMP While Managing Risk
- Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology
- Europe's ATMP Opportunity Still Requires Local Navigation
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-675822670 clean room, lab, scientist]( "Data-Driven CHO Bioprocess Optimization And Scale-Up")
Data-Driven CHO Bioprocess Optimization And Scale-UpLearn how at-line cell culture media analysis enhances mAb production by refining nutrient feed strategies, reducing toxic metabolites, and improving yields while lowering costs.
-
![GettyImages-1181392775 lab, research]( "Predicting Antibody-Dependent Cell-Mediated Cytotoxicity")
Predicting Antibody-Dependent Cell-Mediated CytotoxicityWe developed and validated a dual screening procedure (genotype and phenotype) for Lonza human peripheral blood mononuclear cells (PBMCs) to identify donors with high ADCC potential.
-
![ai-data-GettyImages-2236890597]( "Unlock The Power Of Clinical Data Science")
Unlock The Power Of Clinical Data ScienceDiscover a unified, AI‑driven approach that helps clinical teams manage growing data complexity, accelerate insight generation, and improve trial oversight to enable faster decisions.
-
![GettyImages-2153976466-protein-3d-model-render]( "Measure And Control In-Line Protein Concentration")
Measure And Control In-Line Protein ConcentrationStreamline protein and antibody purification with an automated TFF system featuring real-time, in-line concentration measurement for enhanced accuracy, reliability, and cGMP compliance.
-
![GettyImages-1590576166 cells, research, lab, assay]( "Rapid Production Of Assay Ready Cells For GPCR Drug Discovery")
Rapid Production Of Assay Ready Cells For GPCR Drug DiscoveryAccelerate drug discovery by leveraging transiently transfected assay-ready cells. This method improves assay sensitivity and reduces variability for GPCRs.
-
![GettyImages-1293772880-Lab-Science-Research-Scientist-Discovery-Development]( "Understand Fluorescence And How It Enhances Scientific Exploration")
Understand Fluorescence And How It Enhances Scientific ExplorationDeepen your understanding of fluorescence for research, and gain valuable insight into how to select appropriate fluorophores and fluorescent proteins for your experiments.
-
![Scientists working in lab-GettyImages-542935478]( "How Remote Pharmacy Monitoring Improves Trial Compliance")
How Remote Pharmacy Monitoring Improves Trial ComplianceExplore how leading IDS pharmacies are using remote monitoring workflows and digital accountability systems to improve accuracy, reduce site burden, and maintain audit readiness.
-
![GettyImages-1767170794-GLP-1-peptide-chain]( "GLP-1 Peptides Around The World")
GLP-1 Peptides Around The WorldExplore how evolving regulations, supply constraints, and reimbursement models shape GLP-1 drug development across the U.S., Europe, and Asia.
-
![GettyImages-2181934436-laboratory-analysis-scientists-technology-computer]( "Streamline Analytical Tech Transfer Through Analytical Target Profile")
Streamline Analytical Tech Transfer Through Analytical Target ProfileAnalytics debt in CGT can derail timelines and budgets. Learn how early ATP planning and cross-functional alignment can eliminate costly setbacks and accelerate IND approvals.
-
![GettyImages-1429005105-scientist-ipad-software-management]( "Guiding Principles For Process Development And IND Readiness")
Guiding Principles For Process Development And IND ReadinessObserve how a milestone-driven risk management strategy streamlines cell therapy development, reduces uncertainty, and aligns early decisions with long-term commercialization and regulatory success.
NEWSLETTER ARCHIVE
- 09.04.26 -- New Podcast Episodes: Fixing AAV Recovery, Cell Therapy Advances, Reimagining Solid Tumor Immunotherapy
- 09.04.26 -- The Blueprint For Viral Vector Manufacturing Success
- 09.04.26 -- Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology
- 09.03.26 -- Real-Time Visibility Is Reshaping Outsourced Gene Therapy
- 09.03.26 -- How To Match CGT Manufacturing Models To Pipeline Needs With Legend Biotech
- Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions?
- Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology
- In Vivo CAR T Needs More Than Better Cell Engineering
- Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections
